Advanced Enzyme Technologies Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 355.6 as of 06 May 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 21.1 on March 2021 to 19.7 on March 2025 . This represents a CAGR of -1.36% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 45131 crore on March 2021 to ₹ 89122 crore on March 2025 . This represents a CAGR of 14.58% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 191.66 crore as compare to the Sep '25 revenue of ₹ 194.81 crore. This represent the decline of -1.62% The revenue of Zydus Lifesciences Ltd for the Dec '25 is ₹ 6975 crore as compare to the Sep '25 revenue of ₹ 6232 crore. This represent the growth of 11.93% The ebitda of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 69.07 crore as compare to the Sep '25 ebitda of ₹ 70.34 crore. This represent the decline of -1.81% The ebitda of Zydus Lifesciences Ltd for the Dec '25 is ₹ 1842 crore as compare to the Sep '25 ebitda of ₹ 2090 crore. This represent the decline of -11.85% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 43.18 crore over 7 quarters. This represents a CAGR of 12.79% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 965.1 crore over 7 quarters. This represents a CAGR of -21.18% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 24.28 % on March 2021 to 19.16 % on March 2025 . This represents a CAGR of -4.63% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Zydus Lifesciences Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,980 Cr while Market cap of Zydus Lifesciences Ltd is 94,495 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Zydus Lifesciences Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Zydus Lifesciences Ltd?

As of May 6, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹355.6. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹939.1.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.